[
  {
    "ts": null,
    "headline": "AstraZeneca's Growth Potential: 6 Reasons For A Buy Rating",
    "summary": "AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the companyâs future looks bright.",
    "url": "https://finnhub.io/api/news?id=b0bffa5a9ae5c47a255e185aa2cf65897e628d26de0c5f6cfe30db3a2a88b556",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737639382,
      "headline": "AstraZeneca's Growth Potential: 6 Reasons For A Buy Rating",
      "id": 132449871,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/107429764/image_107429764.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the companyâs future looks bright.",
      "url": "https://finnhub.io/api/news?id=b0bffa5a9ae5c47a255e185aa2cf65897e628d26de0c5f6cfe30db3a2a88b556"
    }
  },
  {
    "ts": null,
    "headline": "Tango Therapeutics: Chance For A Short Squeeze",
    "summary": "Tango Therapeutics is a growing cancer drug development company with partners such as Gilead Sciences. Explore more details here.",
    "url": "https://finnhub.io/api/news?id=4235307b72327f9330318ffcd7ffac1380ae8cc0a672c15b8eec1b2e0d0ad9b0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737611045,
      "headline": "Tango Therapeutics: Chance For A Short Squeeze",
      "id": 132447524,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2183545745/image_2183545745.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Tango Therapeutics is a growing cancer drug development company with partners such as Gilead Sciences. Explore more details here.",
      "url": "https://finnhub.io/api/news?id=4235307b72327f9330318ffcd7ffac1380ae8cc0a672c15b8eec1b2e0d0ad9b0"
    }
  },
  {
    "ts": null,
    "headline": "Dodge & Cox Balanced Fund Q4 2024 Shareholder Letter",
    "summary": "The S&P 500 Index rose by 26.3% in 2023 and posted a 25.0% return in 2024, marking its largest consecutive annual gains since 1998. Read more here.",
    "url": "https://finnhub.io/api/news?id=97d7d2711a0bf68b39f810b96c40aeeb911d9207c46cc97a77dbdf06d2dbc1f1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737598920,
      "headline": "Dodge & Cox Balanced Fund Q4 2024 Shareholder Letter",
      "id": 132446540,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/917884914/image_917884914.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "The S&P 500 Index rose by 26.3% in 2023 and posted a 25.0% return in 2024, marking its largest consecutive annual gains since 1998. Read more here.",
      "url": "https://finnhub.io/api/news?id=97d7d2711a0bf68b39f810b96c40aeeb911d9207c46cc97a77dbdf06d2dbc1f1"
    }
  }
]